Literature DB >> 32597469

Response to letter to the editor: "All models are wrong; some models are useful".

Antje Arnold1, Fausto Rodriguez1, Charles G Eberhart1, Eric H Raabe1,2.   

Abstract

Year:  2020        PMID： 32597469      PMCID： PMC7523438          DOI： 10.1093/neuonc/noaa137

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  7 in total

1.  Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin.

Authors:  Brad Poore; Ming Yuan; Antje Arnold; Antoinette Price; Jesse Alt; Jeffrey A Rubens; Barbara S Slusher; Charles G Eberhart; Eric H Raabe
Journal:  Neuro Oncol       Date:  2019-02-14       Impact factor: 12.300

2.  Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.

Authors:  Jason Fangusaro; Arzu Onar-Thomas; Tina Young Poussaint; Shengjie Wu; Azra H Ligon; Neal Lindeman; Anuradha Banerjee; Roger J Packer; Lindsay B Kilburn; Stewart Goldman; Ian F Pollack; Ibrahim Qaddoumi; Regina I Jakacki; Paul G Fisher; Girish Dhall; Patricia Baxter; Susan G Kreissman; Clinton F Stewart; David T W Jones; Stefan M Pfister; Gilbert Vezina; Jessica S Stern; Ashok Panigrahy; Zoltan Patay; Benita Tamrazi; Jeremy Y Jones; Sofia S Haque; David S Enterline; Soonmee Cha; Michael J Fisher; Laurence Austin Doyle; Malcolm Smith; Ira J Dunkel; Maryam Fouladi
Journal:  Lancet Oncol       Date:  2019-05-28       Impact factor: 41.316

3.  Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.

Authors:  E Anders Kolb; Richard Gorlick; Peter J Houghton; Christopher L Morton; Geoffrey Neale; Stephen T Keir; Hernan Carol; Richard Lock; Doris Phelps; Min H Kang; C Patrick Reynolds; John M Maris; Catherine Billups; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2010-10       Impact factor: 3.167

4.  Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.

Authors:  Craig Horbinski; Marina N Nikiforova; Jill M Hagenkord; Ronald L Hamilton; Ian F Pollack
Journal:  Neuro Oncol       Date:  2012-04-05       Impact factor: 12.300

5.  The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity.

Authors:  Jeffrey A Rubens; Sabrina Z Wang; Antoinette Price; Melanie F Weingart; Sariah J Allen; Brent A Orr; Charles G Eberhart; Eric H Raabe
Journal:  Neuro Oncol       Date:  2017-10-01       Impact factor: 13.029

6.  Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023).

Authors:  AeRang Kim; Yao Lu; Scott H Okuno; Denise Reinke; Ophélia Maertens; John Perentesis; Mitali Basu; Pamela L Wolters; Thomas De Raedt; Sant Chawla; Rashmi Chugh; Brian A Van Tine; Geraldine O'Sullivan; Alice Chen; Karen Cichowski; Brigitte C Widemann
Journal:  Sarcoma       Date:  2020-01-30

7.  MEK/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid/rhabdoid tumors.

Authors:  Michaël H Meel; Miriam Guillén Navarro; Mark C de Gooijer; Dennis S Metselaar; Piotr Waranecki; Marjolein Breur; Tonny Lagerweij; Laurine E Wedekind; Jan Koster; Marianne D van de Wetering; Netteke Schouten-van Meeteren; Eleonora Aronica; Olaf van Tellingen; Marianna Bugiani; Timothy N Phoenix; Gertjan J L Kaspers; Esther Hulleman
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.